Pulmonology5 articles

Impact 3

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Published: 2026-04-01

Lung cancer (Amsterdam, Netherlands)

MediLens Indexed: 2026-04-02

This phase II trial evaluated the efficacy of osimertinib in patients with EGFR-mutated non-small cell lung cancer, focusing on those with untreated brain metastases. The study included 100 patients, showing an overall objective response rate of 72.0%, with 81.8% in those with measurable brain me...

Read on PubMed

Impact 3

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

Published: 2026-04-01

Lung cancer (Amsterdam, Netherlands)

MediLens Indexed: 2026-04-02

The study evaluated the overall survival (OS) of amivantamab-lazertinib compared to osimertinib in Asian patients with untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). Results showed a significant improvement in OS for amivantamab-lazertinib, with a hazard ratio of 0.74 at a me...

Read on PubMed

Impact 3

Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.

Published: 2026-04-01

Oral oncology

MediLens Indexed: 2026-04-02

This study presents a novel classification system for documenting surgical outcomes in patients with sinonasal squamous cell carcinoma (SCC) undergoing neoadjuvant therapy. The framework addresses the complexities of sinonasal anatomy and aims to standardize the evaluation of surgical morbidity a...

Read on PubMed

Impact 3

Xbp1-driven lipid metabolism promotes immunosuppression in lung cancer: Jianpi Chutan Jiedu formula reshapes metabolic-immune crosstalk.

Published: 2026-04-01

Phytomedicine : international journal of phytotherapy and phytopharmacology

MediLens Indexed: 2026-04-02

This study investigates the antitumor efficacy of the Jianpi Chutan Jiedu Formula (JCJ) in lung cancer (LC) and its underlying mechanisms. It identifies high expression of XBP1 in LC and demonstrates that Xbp1 overexpression leads to lipid accumulation and immunosuppression in the tumor microenvi...

Read on PubMed

Impact 3

Pediatric Invasive Group A Streptococcus Infections with Central Nervous System Involvement: A Single Institution Case Series in Southern New England.

Published: 2026-04-01

Rhode Island medical journal (2013)

MediLens Indexed: 2026-04-02

This case series highlights three rare pediatric cases of invasive Group A Streptococcus (iGAS) infections with central nervous system involvement, all occurring within a two-month period in Massachusetts. The patients presented with severe conditions, including meningitis and subdural collection...

Read on PubMed

Medical Research Trends

Pulmonology5 articles

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.

Xbp1-driven lipid metabolism promotes immunosuppression in lung cancer: Jianpi Chutan Jiedu formula reshapes metabolic-immune crosstalk.

Pediatric Invasive Group A Streptococcus Infections with Central Nervous System Involvement: A Single Institution Case Series in Southern New England.

Get Personalized Daily Summaries